Latest news with #VIVID
Time of India
a day ago
- Entertainment
- Time of India
MYNAME marks its return with new mini EP 'VIVID' after a 7-year hiatus; Elated fans react
Boy Group MYNAME has returned! The idol group debuted back in 2011 and had remained fairly inactive after their disbandment in 2019. The group recently made their comeback to the music industry after a seven-year hiatus. MYNAME returns after 7 years with new EP K-pop idol group MYNAME, who had debuted in 2011 and had last released a Japanese album in 2018, have officially returned with their new mini EP titled 'VIVID', with the title song 'Bad Bad Higher' on July 2. MYNAME are back with their first Japanese mini album in 7 years, 'VIVID', and the title track 'BAD BAD HIGHER'! The choreography was made by DA PUMP's KENZO and pays hommage to MYNAME's debut song 'Message'. @myname_jp — nugu archive 📁 (@nugupromo) July 2, 2025 The mini EP consists of tracks created by 3 of the five original members: Gunwoo, Insoo, and Seyong, while the remaining two are still credited to be part of the group. It has a total of 6 tracks in total. As soon as the news about the idol group's new mini EP and single dropped, fans went into a frenzy and started celebrating the milestone. Fans react to the comeback As soon as the songs and music videos dropped online on the popular video streaming platform, fans went haywire. Expressing excitement over the new music, one fan commented that "I liked the song, the rhythm, everything was good. I hope to keep listening to this song and I hope to hear more songs. MYNAME is excellent, the best," while another continued, sharing that "Feel awesome to look myname again!!" A third fan shared a comment saying, "There isn't enough volume for MyName!!!" About MYNAME MYNAME debuted in 2011 and was formed directly by Fly to the Sky's Hwanhee. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo Ever since their debut, the group has seen major success in Japan and has extensively worked on releasing Japanese content throughout their tenure. After being active for almost 8 years, the group's official management agency announced in 2019 that the group members had decided not to renew their contracts with their original company, causing the group to disband. While fans expressed their disappointment at the time, it was Seyoung, a fellow member of MYNAME, who mentioned that the rumour was false. Their contracts expired, but they were still a group. At the time, he also released a statement about how the group had still been actively promoting Japan.
Yahoo
02-04-2025
- Business
- Yahoo
Scientific Industries Inc (SCND) Q4 2024 Earnings Call Highlights: Strategic Growth and ...
Release Date: April 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Scientific Industries Inc (SCND) welcomed two valuable board members with expertise in synthetic biology and pharma process control, positioning the company for significant growth. The company streamlined its organization, reducing operating expenses by nearly $3 million and cash used in operations by $2.5 million. The launch of the VIVID pharmacy automation product line's final hardware component, the workstation, is expected to improve pharmacy workflow and system integration. The Bioprocessing segment made significant strides in product development and commercialization, with a strong pipeline of opportunities for fiscal 2025. Sales in the Bioprocessing segment increased by 24% compared to 2023, with a reduction in net loss by around $1 million, indicating improved financial performance. The lab equipment industry faced challenges related to destocking from COVID inventory build-out and other economic factors, leading to a 3.6% decline in Genie product line sales. The bioprocessing industry continues to face a complex environment with slower than anticipated market recovery due to post-COVID inventory correction and conservative capital allocation. Trade conflicts, geopolitical tensions, and increased regulatory requirements have disrupted supply chains and prolonged procurement timelines. Economic growth in Europe was slow, and budget constraints have extended decision cycles, affecting the company's operations. In the US, research-driven players are deferring investments due to federal budget and grant freezes, impacting technology adoption and market predictability. Warning! GuruFocus has detected 2 Warning Signs with SCND. Q: Can you elaborate on the financial performance of the Bioprocessing segment in 2024? A: Daniel Donadille, CEO of SBI, reported that the Bioprocessing segment saw a 24% increase in sales compared to 2023, with stable gross margins and reduced expenditures leading to a net loss reduction of around $1 million. Despite building $285,000 in reserves, operative gross margins improved to over 70%, driven by the new platform. Q: What are the expectations for the VIVID pharmacy automation product line? A: Helena Santos, CEO, highlighted the launch of the VIVID workstation, a state-of-the-art pill counter that integrates high precision counting with pharmacy management functions. The product has been well-received, with the first six units sold through Rx Systems, and there is potential to replace 13,000 existing units and target 20,000 independent pharmacies. Q: How did the Benchtop Laboratory Equipment segment perform in 2024? A: Helena Santos noted that despite challenges in the lab equipment industry, the Genie product line sales were only 3.6% lower than the previous year. The segment faced issues related to destocking from COVID inventory build-out and other economic factors. Q: What strategic changes were made in 2024 to improve operational efficiency? A: Helena Santos mentioned that the company streamlined its organization, reducing operating expenses by nearly $3 million and cash used in operations by $2.5 million. This was part of a broader effort to position the company for significant growth. Q: What are the future projections for the Bioprocessing segment? A: Daniel Donadille expressed optimism for a market rebound, with the global bioprocessing tools market expected to return to double-digit growth. The company plans to launch new technologies, including a pH sensor and a second-generation liquid injection system, to capitalize on this growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
